Welcome to our dedicated page for Enanta Pharmaceuticals news (Ticker: ENTA), a resource for investors and traders seeking the latest updates and insights on Enanta Pharmaceuticals stock.
News and updates for Enanta Pharmaceuticals, Inc. (ENTA) focus on its progress as a clinical-stage biotechnology company developing small molecule drugs for viral infections and immunological diseases. Company press releases frequently highlight clinical data, regulatory designations, pipeline milestones, financial results, capital raises, and intellectual property developments.
Investors following ENTA news can expect detailed coverage of RSV clinical programs, including zelicapavir, an oral N-protein inhibitor, and EDP-323, an oral L-protein inhibitor. Enanta regularly reports Phase 2 and Phase 2b trial readouts in high-risk adult and pediatric RSV populations, human viral challenge data, and analyses of symptom resolution, viral load reductions, and safety outcomes. Updates also cover Phase 3-enabling activities and interactions with the U.S. Food and Drug Administration on trial design and registration pathways.
News items also track Enanta’s immunology pipeline, such as the nomination of EPS-3903, an oral STAT6 inhibitor for atopic dermatitis and other type 2 immune-driven diseases, and the selection of EDP-978, an oral KIT inhibitor for chronic spontaneous urticaria and other mast cell–driven conditions. Announcements describe preclinical potency, selectivity, and planned IND filings and early clinical timelines, as well as the expansion of discovery programs targeting MRGPRX2.
On the corporate side, ENTA news includes quarterly and annual financial results, commentary on royalty revenue from AbbVie’s HCV regimen MAVYRET/MAVIRET, and disclosures about cash runway expectations. Coverage also includes public equity offerings, underwritten offering terms, and use of proceeds, along with patent litigation developments, such as Enanta’s infringement action in the Unified Patent Court related to its coronavirus protease inhibitor patent. For ongoing insight into ENTA’s clinical, financial, and legal developments, this news feed aggregates the company’s latest official announcements.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced key participation in upcoming conferences. CEO Jay R. Luly will engage in a Fireside Chat at the Evercore ISI 3rd Annual Virtual HealthCONx Conference on December 1, 2020, at 9:15 a.m. ET. Additionally, he will take part in One-on-One Meetings during the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 2, 2020, with a Fireside Chat available from November 25. Enanta focuses on developing small molecule drugs for viral infections and liver diseases, funded by royalties from its collaboration with AbbVie.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced plans to report its financial results for the fiscal fourth quarter and year ended September 30, 2020, on November 23, 2020, after market close. A conference call will be held at 4:30 p.m. ET on the same day to discuss the results and provide updates on its business, including research and development efforts in viral infections and liver diseases. Enanta's research is funded by royalties from its collaboration with AbbVie, notably for its hepatitis C drug, Glecaprevir.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company, announced that CEO Jay R. Luly, Ph.D., will participate in a fireside chat at the 4th Annual H.C. Wainwright Virtual NASH Investor Conference on October 5, 2020, at 2:00 pm ET. The event will be accessible via a live webcast on Enanta’s website, with a replay available for 30 days post-presentation.
Enanta focuses on developing small molecule drugs for viral infections and liver diseases, with ongoing research in RSV, NASH, HBV, and COVID-19.